MMJ International Holdings is pursuing FDA-approved cannabinoid medicines.
3 reports, 2 independent
Updated Sep 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MMJ International Holdings is pursuing FDA-approved cannabinoid medicines.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.MMJ challenges FDA product approval standards for marijuana.1 source
MMJ International Holdings is pursuing FDA-approved cannabinoid medicines.1 source
Keep exploring
The entities involved
Related events
- Agencies (FDA and DEA) implement a regulatory shift concerning cannabis.
- FDA approval enables commercial opportunity involving CBRE Group.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.